Search

everythinglearnresearchcommunity

for

Search:↓

A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.

Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.

5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Older adults have a high rate of skin cancers like basal cell carcinoma and melanoma, mainly due to UV exposure and age.

Finasteride helps reduce priapism in sickle cell anemia patients.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.

Tamoxifen caused hair loss in a 52-year-old woman.

Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.

Effective, well-tolerated, and affordable treatments are needed for recurrent ischemic priapism.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Breast cancer patients need strong psychological support to improve their quality of life.

Hair loss due to scalp metastasis from breast cancer, known as Neoplastic Alopecia, has a better survival rate than other scalp metastases and requires a biopsy for diagnosis.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Docetaxel chemotherapy causes more long-term hair loss and dissatisfaction than paclitaxel.

Certain plasma proteins are linked to prostate cancer risk and could help in early detection and treatment.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Fasting may reduce chemotherapy side effects.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.